Moreover, the Jianpi-Jiedu formula (JPJDF) can improve the survival rate in patients with stage II and III CRC and inhibits tumorigenesis, metastasis, and angiogenesis through the mTOR/HIF-1alpha/VEGF pathway in CRC (Wu et al., 2019a). The gene discussed is MTOR; the disease is colorectal carcinoma.